Medikal Teknik Ocak 2018

AKTÜEL
Eczacıbaşı-Monrol continues to invest in
nuclear medicine
Eczacıbaşı-Monrol that is joint venture between Eczacibasi
Pharmaceuticals Manufacturing and Bozlu Nuclear Products in 2008,
continues to lead the development of Turkey’s nuclear medicine market
through the production of high-quality radiopharmaceuticals for
diagnosis and treatment. Eczacıbaşı-Monrol announced that in 2018 it
will start production of Tc99M Generator, which is the second plant in
this area in Egypt.
Eczacıbaşı-Monrol continues
to invest in the field of Nuclear
Medicine with the production
of Tc99M Generator which is
planned to start in Egypt in 2018
and continues production of high
quality radiopharmaceutical used
in the diagnosis and treatment of
diseases. Eczacıbaşı-Monrol has 9
world-class production facilities, 6
in Turkey and 3 abroad (Bulgaria,
Romania and Egypt), employing
modern and environment-friendly
technologies. The company also
has been operating cyclotrons in
Kuwait and United Arab Emirates.
Eczacıbaşı-Monrol have a strong
partnership in Dubai with Almulla
Group, one of the most important
conglomerates of UAE under the
name Monrol Gulf, for many years.
Eczacıbaşı-Monrol, which operates
the cyclotron plant of Almulla
Group, operates a cyclotron plant
in Kuwait, which is affiliated to the
Ministry of Health, with its local
partners.
in Turkey and more than 30
countries around the world without
compromising on quality and
customer-oriented service. There
are 2 continuous cyclotron plant
projects in Pakistan and Erbil.
Eczacıbaşı-Monrol whose
headquarters is located in Ataşehir,
has been serving with its 300
employees and 5 distributors to
supply nuclear medicine centers
Ocak 2018
35